/ /

CLINICAL

Research suggests new approaches to treat AD
Research suggests new approaches to treat ADResearch aimed at understanding the host-microbial interface in atopic dermatitis is ongoing but already providing insights for novel therapeutic strategies.
FDA approves corticosteroid-sparing topical option for eczemaThe FDA announced it has approved Eucrisa (Anacor Pharmaceuticals, crisaborole) ointment to treat mild to moderate eczema in patients two-years-of-age and older.
Rosacea treatmentsNewer topical agents for rosacea including ivermectin and brimonidine are effective, and soon could be joined by oxymetazoline cream, experts say. Initial results from phase 2 trials of minocycline foam in rosacea could be available by year's end.
Factors in rosacea pathogenesis clearerKeeping abreast of findings regarding the immunological, neurological and vascular roots of rosacea helps dermatologists target treatments accordingly, experts say.
Will new autoimmune drugs address cost concerns?Find out what’s in the drug pipeline for autoimmune disease.
The digital skin health revolutionMobile app for acne opens the door for use with skin aging and other aesthetic skin conditions.
Dermatology’s 2017 Game ChangersSeveral dermatologists go over what they're most excited about to see in 2017 in a number of different topics ranging from AD treatment to off-label technology use, to more male patients.
First-ever U.S. psoriasis treatment goalsThe National Psoriasis Foundation has recently published psoriasis treatment goals, which will help physicians and patients discuss treatment options and set expectations for outcomes.
December Clinical Considerations for NPs, PAsIn this month's Clinical Considerations, we take a look at AD and bullying, whether or not derms are doing enough for psoriasis patients, and the potential of Epicutaneous immunotherapy.
Novel immunomodulators expected to usher in new therapeutic eraA number of systemic and topical treatments for atopic dermatitis are being developed that feature novel mechanisms of action targeting the inflammatory axes involved in the disease.

Poll

View Results